Pharmaceutical Executive January 17, 2025
Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.
The development of cell and gene therapies could be considered one of the most important developments in the pharma industry. However, while these treatments have shown the capability to be highly effective, there are still a significant number of hurdles keeping them from becoming more widespread.
Jason Foster, CEO of Ori Biotech, spoke with Endpoints News founder Arsalan Arif at the JP Morgan Healthcare Conference in San Francisco, which was held from January 13-16 this year. During the conversation, Arif asked Foster about Ori’s patient tracker, which keeps a count of the number of patients treated with CAR T therapies. According to this...
Today's Sponsors
Today's Sponsor